Mission Statement, Vision, & Core Values (2026) of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Founded in 2002, Sunshine Guojian Pharmaceutical (688336.SS) blends a bold mission-"Benefit China and embrace the world, making innovative antibody drugs within reach"-with tangible capabilities, operating a production base exceeding 40,000 liters and hosting the National Engineering Research Center of Antibody Medicine to drive R&D, manufacturing and commercialization of therapeutic antibodies for autoimmune diseases, tumors and other major conditions; the company secured a landmark FDA 2020 clinical trial approval for an anti-IL-4Rα monoclonal antibody, has core products approved in over 15 countries with registrations in more than 20, and backs its patient-centered vision with measurable commitments-donating over $2 million to local health programs in 2023, achieving a 99% pass rate in regulatory product inspections in 2023 and targeting a 15% reduction in carbon footprint by the end of 2024-details that reveal how its values of innovation, integrity, collaboration and accessibility translate into global reach and measurable impact.

Sunshine Guojian Pharmaceutical Co., Ltd (688336.SS) - Intro

• Founded: 2002 (Shanghai)
• Specialization: Innovative therapeutic monoclonal antibodies
• Production base: >40,000 L bioreactor capacity
• National asset: Hosts National Engineering Research Center of Antibody Medicine
• Global approvals/registrations: approved in 15+ countries, registered in 20+ countries
• Regulatory milestone: FDA clinical trial approval (anti-IL-4Rα) - 2020

Mission

• Develop safe, effective and accessible antibody therapies that transform treatment paradigms for patients with autoimmune disease, cancer and serious unmet medical needs.
• Advance China-origin innovative biologics to global standards through rigorous science, manufacturing excellence and regulatory compliance.

Vision

• Be a globally recognized biopharmaceutical innovator originating from China, delivering multiple first-in-class or best-in-class antibody therapies to patients worldwide.
• Create a scalable platform that accelerates translation from discovery to global commercialization while enabling strategic partnerships and licensing.

Core Values

• Science-led innovation: prioritize rigorous, evidence-driven R&D.
• Patient-centricity: align decisions with patient safety, access and outcomes.
• Quality & compliance: adhere to global GMP, GLP and GCP standards.
• Collaboration & integrity: foster open partnerships and ethical conduct.
• Operational excellence: continuous improvement in manufacturing and supply reliability.

Selected operational & financial indicators (latest available)

Strategic priorities tied to mission & vision

• Accelerate clinical development of first-in-class candidates while sustaining CMC scale-up to ensure timely commercial supply.
• Expand global regulatory approvals and commercialization footprint through localized registrations and partnerships.
• Invest in platform technologies (antibody engineering, bispecifics, ADC linkers) to broaden therapeutic modalities.
• Strengthen manufacturing redundancy and quality governance to meet global GMP requirements.

Relevant investor context and further corporate details: Exploring Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd Investor Profile: Who's Buying and Why?

Sunshine Guojian Pharmaceutical Co., Ltd (688336.SS) - Overview

Mission: 'Benefit China and embrace the world, making innovative antibody drugs within reach.' This mission frames Sunshine Guojian's strategic priorities: improve domestic healthcare through antibody innovation, pursue global impact, and drive affordability and accessibility across therapeutic areas.

• Make advanced monoclonal and bispecific antibody therapies accessible to patients in China and internationally.
• Prioritize affordability and scalable manufacturing to lower treatment barriers.
• Advance translational research to accelerate clinical development from bench to bedside.
• Expand regulatory and commercial footprints beyond China through partnerships and global trials.

Strategic alignment with the mission is reflected in measurable investments and milestones across R&D, clinical development, and manufacturing capacity. Key operational and strategic areas include:

• R&D intensity - sustained high share of revenue allocated to discovery and clinical programs.
• Pipeline breadth - multi-program antibody portfolio targeting oncology and immunology indications.
• Globalization - initiation of multinational clinical trials and filings in overseas regulatory jurisdictions.
• Affordability initiatives - cost-efficient biologics manufacturing and patient access programs.

Core values and cultural principles that operationalize the mission:

• Patient-centricity - prioritize clinical benefit and accessibility in portfolio decisions.
• Scientific rigor - invest in cutting-edge antibody engineering and translational science.
• Integrity & compliance - adhere to global regulatory standards across trials and manufacturing.
• Collaboration - pursue partnerships with academic centers, CROs, and international biopharma.
• Sustainability - scale manufacturing with cost and resource efficiency to improve affordability.

Examples of mission-driven initiatives and measurable outcomes:

• Pipeline acceleration - moved multiple antibody candidates from IND to early clinical stages within 24 months, reducing time-to-clinic.
• Affordability programs - tiered-pricing strategies and patient assistance pilots in selected oncology indications.
• R&D partnerships - co-development agreements with domestic and overseas research institutes to access novel targets and technologies.
• Quality and scale-up - validation of commercial-scale GMP processes enabling projected annual supply for tens of thousands of treatment cycles.

For a deeper review of corporate history, ownership and how Sunshine Guojian operates within the broader biotech landscape, see: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd: History, Ownership, Mission, How It Works & Makes Money

Sunshine Guojian Pharmaceutical Co., Ltd (688336.SS) - Mission Statement

• Patient-oriented innovation: prioritize unmet clinical needs and deliver targeted antibody drugs that improve clinical outcomes and quality of life.
• End-to-end capability: integrate R&D, GMP manufacturing and commercialization to shorten time-to-market and ensure supply security.
• Access and affordability: widen patient access through strategic pricing, partnerships and registration in global markets.
• Sustainable operations: reduce environmental impact across R&D and manufacturing, including a target to cut carbon emissions by 15% by the end of 2024.

• Provide high-quality, safe and effective clinical solutions to contribute meaningfully to Healthy China initiatives.
• Make innovative antibody drugs accessible to a broader population, enhancing health outcomes domestically and globally.
• Adopt a patient-centered development model that aligns indications, dosing and delivery with real-world patient needs.
• Expand international presence so core products are approved in over 15 countries and registered in more than 20 countries.

• Accelerate late-stage clinical programs with adaptive trial designs and real-world evidence integration to shorten approval timelines.
• Expand commercial footprint via partnerships and licensing in APAC, EMEA and select global markets to achieve multi-country approvals and registrations.
• Invest in biologics manufacturing scale-up and digital quality systems to ensure consistent supply and cost-efficient production.
• Embed environmental, social and governance (ESG) practices across operations to meet the -15% carbon target and improve resource efficiency.

Sunshine Guojian Pharmaceutical Co., Ltd (688336.SS) - Vision Statement

• Innovation: relentless R&D focus to advance novel therapeutics and platform technologies
• Excellence: adherence to rigorous quality standards across development, manufacturing, and distribution
• Focus & Persistence: patient-centered pipelines with disciplined clinical and regulatory execution
• Collaboration & Sharing: strategic alliances with research institutions worldwide to accelerate translation
• Integrity: commitment to ethical practices, transparency, and compliance
• Social Responsibility: sustained investment in community health and public-good initiatives

• R&D acceleration via global partnerships and shared innovation platforms
• Quality-first manufacturing with sustained regulatory excellence (99% pass rate in 2023)
• Responsible corporate citizenship-over $2M donated to community health initiatives in 2023
• Environmental stewardship-targeted 15% carbon reduction by end-2024 aligned with global sustainability goals